|
Price: $126.2800
$0.01 
0.008%
|
| Day's High:
| $128.63
| Week Perf:
| -2.41 %
|
| Day's Low: |
$ 125.97 |
30 Day Perf: |
3.65 % |
| Volume (M): |
340 |
52 Wk High: |
$ 136.61 |
| Volume (M$): |
$ 42,910 |
52 Wk Avg: |
$95.05 |
| Open: |
$126.76 |
52 Wk Low: |
$59.22 |
|
|
| Market Capitalization (Millions $) |
6,404 |
| Shares
Outstanding (Millions) |
51 |
| Employees |
900 |
| Revenues (TTM) (Millions $) |
340 |
| Net Income (TTM) (Millions $) |
-159 |
| Cash Flow (TTM) (Millions $) |
-28 |
| Capital Exp. (TTM) (Millions $) |
11 |
Glaukos Corp
Glaukos Corporation is a medical technology company that focuses on developing and commercializing products and procedures to treat glaucoma, one of the leading causes of blindness worldwide. It was founded in 1998 and is headquartered in San Clemente, California, United States.
Glaukos Corporation offers a broad range of innovative glaucoma treatments that are designed to offer safe, long-lasting, and effective relief to patients suffering from this debilitating eye disease. The company's flagship product is the iStent, which is the world's first micro-bypass stent approved for use in patients with mild to moderate open-angle glaucoma. This tiny stent is placed into the eye during a minimally invasive procedure, through which it helps to alleviate intraocular pressure by improving the drainage of fluid from the eye.
Beyond the iStent, Glaukos offers a suite of glaucoma products that leverage the company's expertise in micro-scale devices and implantable technologies. These products include the iStent Inject, a next-generation version of the iStent that offers increased flow through two stents, as well as the iStent SA, which is designed for use in patients who are undergoing cataract surgery.
In addition to its product offerings, Glaukos has a robust research and development program that is focused on advancing the field of glaucoma treatment. This includes a pipeline of novel devices, surgical systems, and drug-delivery technologies that aim to address unmet needs in the glaucoma market.
The company's strong growth in recent years has been driven by its ability to provide compelling solutions to a significant unmet need in the ophthalmology marketplace. In 2020, Glaukos generated revenues of $196 million, a7% increase from the previous year.
Overall, Glaukos Corporation is a leading player in the ophthalmology space, with a strong track record of innovation and a commitment to improving patients' lives. As the company continues to invest in research and development, it is well-positioned to remain a key player in the glaucoma market for years to come.
Company Address: One Glaukos Way Aliso Viejo 92656 CA
Company Phone Number: 367-9600 Stock Exchange / Ticker: NYSE GKOS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Fri, Jun 14 2024 12:47 PM UTC
Glaukos Corporation's Strategic Exchange Agreements Pave the Path for Growth and SuccessALISO VIEJO, Calif. - Glaukos Corporation (NYSE: GKOS), the renowned ophthalmic pharmaceutical and medical technology company, has recently taken a significant step towards strengthening its financial position and unlocking further opportunities for growth. The company has announced the e...
|
| Glaukos Corp
Glaukos Corp is a prominent ophthalmic pharmaceutical and medical technology company that focuses on developing novel therapies for treating glaucoma, corneal disorders, and retinal diseases. In April 2024, the company witnessed a decline of 4.4% in its stock, which brought the share price down to 4.4% during the second quarter of that year. Despite this decline, Glaukos Corp's stock is currently trending higher, with just 5% below its 52-week high.
To assess the company's financial performance, let's examine the results for the January to March 31, 2024 fiscal interval. During this period, Glaukos Corp experienced a deficit per share of $-0.82, compared to $-0.72 the previous year. This signifies an increased deficit when compared to the preceding quarter's $-0.74 per share.
However, the company's revenue showcased positive growth. In the corresponding quarter of the previous year, Glaukos Corp's revenue increased by an admirable 15.514% to $85.36 million from $73.90 million. Sequentially, revenue advanced by 3.723% from $82.30 million. It is noteworthy that this revenue improvement correlates favorably to its peers in the Medical Equipment & Supplies industry, which reported an overall business rise of 6.18% during the same time period.
|
| Glaukos Corp
Glaukos Corp, a leading ophthalmic pharmaceutical and medical technology company, has seen a significant improvement in their stock performance over the past year. The stock has improved by an impressive 87.23%, bringing the share price to a 18.66% increase during the first quarter of 2024. This upward trend in stock performance is further supported by the fact that Glaukos Corp is just 5.9% short off its 52-week high.
Despite this positive stock performance, Glaukos Corp did experience a loss per share of $-0.74 in the most recent fiscal period, compared to $-0.66 a year before. Furthermore, the loss per share has increased from $-0.63 in the prior financial reporting period. However, it's important to note that while the loss per share has widened, the revenue has grown admirably by 15.546% to $82.30 million from $71.23 million in the comparable financial reporting period a year before. Additionally, the revenue has also increased by 6.142% sequentially, from $77.54 million.
|
| Business Update
Published Tue, Jan 9 2024 12:00 PM UTC
Aliso Viejo, Calif. ?? Glaukos Corporation (NYSE: GKOS), a leading ophthalmic medical technology and pharmaceutical company specializing in innovative therapies for glaucoma, corneal disorders, and retinal diseases, has announced its preliminary, unaudited net sales for the fourth quarter and full year ended December 31, 2023.With great excitement, Glaukos reveals that their...
|
| Contract
Published Thu, Dec 14 2023 12:00 PM UTC
Glaukos Corporation Receives FDA Approval for iDose TR, Presenting Positive Growth Prospects in the Glaucoma Market
Glaukos Corporation, a leading ophthalmic medical technology and pharmaceutical company specializing in innovative treatments for glaucoma, corneal disorders, and retinal diseases, has recently announced the approval of its New Drug Application (NDA) b...
|
| Per Share |
Current |
| Earnings (TTM) |
-3.19 $ |
| Revenues (TTM) |
6.71 $
|
| Cash Flow (TTM) |
- |
| Cash |
5.16 $
|
| Book Value |
13.12 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-3.19 $
|
| Revenues (TTM) |
6.71 $ |
| Cash Flow (TTM) |
- |
| Cash |
5.16 $
|
| Book Value |
13.12 $ |
| Dividend (TTM) |
0 $ |
|
|
| |
| United States |
|
 69.83 % |
of total Revenue |
| International |
|
30.17 % |
of total Revenue |
| Glaucoma |
|
79.3 % |
of total Revenue |
| Glaucoma United States |
|
51.99 % |
of total Revenue |
| Glaucoma International |
|
27.31 % |
of total Revenue |
| Corneal Health |
|
20.7 % |
of total Revenue |
| Corneal Health United States |
|
17.84 % |
of total Revenue |
| Corneal Health International |
|
2.86 % |
of total Revenue |
| |
On January 9 2024 the Glaukos provided following guidance
Based on the latest information, Glaukos Corporation (NYSE: GKOS) has announced its preliminary, unaudited net sales for the fourth quarter and full year of 2023. The company, which specializes in ophthalmic medical technology and pharmaceuticals for the treatment of glaucoma, corneal disorders, and retinal diseases, anticipates total net sales of over $81 million for the fourth quarter and over $313 million for the full year ended December 31, 2023.
This announcement reaffirms Glaukos' 2024 revenue guidance, demonstrating the company's confidence in its future financial performance. As an innovative provider of therapies in the ophthalmic field, Glaukos continues to make significant progress in addre...
|
|
|
